* Apyx Medical Corp APYX.OQ APYX.O is expected to show a
rise in quarterly revenue when it reports results on November
11.
* The Clearwater, Florida-based company is expected to report a
46.6% increase in revenue to $10.196 million from $6.95 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Apyx Medical Corp is
for a loss of 15 cents per share. For the same quarter last
year, the company reported a loss of 11 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Apyx Medical
Corp is $14, about 6.3% below its last closing price
of $14.88.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2021 -0.16 -0.15 -0.12 Beat 18.5
Mar. 31 2021 -0.14 -0.14 -0.14 Met 1.8
Dec. 31 2020 -0.11 -0.11 -0.04 Beat 64.3
Sep. 30 2020 -0.16 -0.17 -0.11 Beat 33.4
Jun. -0.20 -0.21 -0.14 Beat 34.1
30 2020
Mar. 31 2020 -0.25 -0.25 -0.20 Beat 20
Dec. 31 2019 -0.19 -0.16 Beat 17.2
Sep. 30 2019 -0.18 -0.18 -0.13 Beat 27.8
This summary was machine generated November 10 at 02:35 GMT.
All figures in US dollars unless otherwise stated